The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every three weeks in combination with docetaxel (Taxotere) in the treatment of patients with non-small cell lung cancer that is resistant to platinum-based chemotherapy.

Inclusion criteria include:

• Histologically confirmed non-small cell bronchogenic carcinoma, including squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma, mixed (adenocarcinoma with squamous cell carcinoma), bronchoalveolar carcinoma, or large cell carcinoma
• Stage IV or Stage IIIB
• Progressed during or after first-line therapies with platinum-containing regimens in the advanced or metastatic treatment regimen
• At least 18 years of age
• Good performance status (ECOG 0 to 1)
• Adequate liver, renal, and bone marrow function

Exclusion criteria include:

• Pregnant or lactating women
• Treatment with more than one cytotoxic therapy
• Prior radiation to the whole pelvis
• Unstable medical conditions such as uncontrolled cardiac arrhythmia
• Patients with known history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80